An Introduction to Gastrointestinal Cancers
Despite advances in radiotherapy, chemotherapy, and targeted therapy for gastrointestinal cancers, the disease has high recurrence rates and a poor prognosis. However, increased understanding of molecular biology has enabled significant progress in the management of oesophageal, gastric, liver, colorectal and pancreatic malignancies. Immunotherapies such as PD1 inhibitors plus HER-targeted therapies have improved survival in several gastrointestinal tumour types, while PARP inhibitors have been introduced as first-line maintenance treatment for BRCA-mutated metastatic pancreatic cancer.
Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape.
Our supporting partners do not constitute an endorsement of the content on this page.
Gastrointestinal Cancers Content
Upper gastrointestinal cancer highlights – KEYNOTE-585, KEYNOTE-811, MATTERHORN and SANO: Ken Kato, ASCO 2023
Data released from the KEYNOTE-585 (NCT03221426), KEYNOTE-811 (NCT03615326), MATTERHORN (NCT04592913) and SANO (NCT05491616) trials, were some of the most anticipated results and highlights in upper gastrointestinal cancer presented at EMSO 2023. To summarise the findings from these key studies and their impact on the treatment of upper gastrointestinal cancers we caught up with esophageal oncologist […]
Incorporation of Combination Immunotherapy into the Treatment Paradigms of Gastrointestinal Cancers
touchREVIEWS in Oncology & Haematology. 2023;19(2):1–6:Online ahead of journal publication
The field of immuno-oncology has provided novel therapeutic agents that have led to significant improvements in patient outcomes across many tumour types. There have also been great efforts to incorporate immunotherapy (IO) into the treatment paradigms of gastrointestinal (GI) cancers. Across GI tumour types, enhanced efficacy has been seen when these agents are used in […]
Fulfilling the potential of HER2-targeting in colorectal cancer: An update on detection and management
Watch three experts provide insights on detecting HER2 amplifications, guideline-recommended HER2-targeted therapies in mCRC and future perspectives.
- Discuss the importance of and approaches for detecting HER2 amplifications in patients with CRC
- Summarize clinical efficacy data for guideline-recommended HER2-targeted treatments for patients with mCRC
- Appraise investigational evidence and future perspectives for emerging HER2-targeting approaches in HER2-amplified CRC
Thierry André, ASCO 2023: The SOLISTICE phase III study, trifluridine/tipiracil+bevacizumab in patients with unresectable metastatic colorectal cancer
The SOLISTICE phase III study aimed to assess trifluridine/tipiracil+bevacizumab in patients with unresectable metastatic colorectal cancer. In this touchONCOLOGY interview, we speak with Dr Thierry André (Hôpital Saint-Antoine, Paris, France) to discuss the rationale for the use of trifluridine/tipiracil+bevacizumab in patients with unresectable metastatic colorectal cancer, the secondary endpoint of overall survival and the key […]
Michael K Gibson, ASCO 2023: Highlights in upper GI oncology
touchONCOLOGY spoke with editorial board member Michael K Gibson (Vanderbilt University, Nashville, TN, USA) to discuss his highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting, 2–6, June 2023 in the field of upper GI oncology, including the phase 3 ATTRACTION-5 study and a randomized, phase II study assessing toripalimab for the treatment […]
Ben Weinberg, ASCO 2023: Highlights from the PROSPECT, AtezoTRIBE, D-ToRCH and DESTINY-CRC02 trials
touchONCOLOGY spoke with editorial board member Ben Weinberg (Georgetown University, Washington, DC, USA) to discuss his highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting, 2–6, June 2023. This includes data from the Plenary Session randomized phase 3 noninferiority PROSPECT trial, showing that neoadjuvant FOLFOX with selective use of 5-FU chemoradiotherapy (5-FU CRT) […]
Ken Kato, ASCO 2023: Highlights in upper gastrointestinal cancers
touchONCOLOGY are joined by editorial board member Dr Ken Kato (National Cancer Centre Hospital, Tokyo, Japan) to discuss a few of his highlights from the 2023 American Society of Clinical Oncology (ASCO) annual meeting. ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or […]
Michael Pishvaian, AACR 2023: TIGeR-PaC phase III trial, intra-arterial gemcitabine for patients with locally advanced pancreatic cancer
Treatment of locally advanced pancreatic cancer has really primarily consisted of systemic intravenous chemotherapy. The TIGeR-PaC trial is aiming to assess if an alternative treatment mode, intra-arterial delivery of gemcitabine, improves overall survival. In this touchONCOLOGY interview, we speak with Dr Michael Pishvaian (Johns Hopkins University School of Medicine, Baltimore, MD, USA) to discuss the […]
Michael Pishvaian, AACR 2023: Challenges in the treatment of locally advanced pancreatic cancer
Locally advanced pancreatic cancer represents around 30% of all newly diagnosed pancreatic cancers and can be challenging to treat. In this touchONCOLOGY interview, we speak with Dr Michael Pishvaian (Johns Hopkins University School of Medicine, Baltimore, MD, USA) to discuss the challenges in the treatment of locally advanced pancreatic cancer. Dr Pishvaian presented an abstract […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!